Nu-Med Plus, Inc.
NUMD · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | 4.21 | 0.12 | 0.04 |
| FCF Yield | -0.35% | -2.01% | -2.92% | -8.05% |
| EV / EBITDA | 0.00 | -28.74 | -7.84 | -3.14 |
| Quality | ||||
| ROIC | 55.02% | 257.80% | -509.02% | 723.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.06 | 0.53 | 0.30 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 93.32% | -72.53% | 81.40% | 50.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.79 | -0.16 | 0.00 |
| Interest Coverage | -12.63 | -24.11 | -182.17 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,533.76 | -1,169.77 | -851.41 |